The prevalence of NASH is increasing while no drug treatment is currently available. Liver biopsies remain the gold standard for its diagnosis. Currently, NASH histologic assessment is semi-quantitative using different scores (e.g., SAF, Kleiner…) where measures are scaled (e.g.: from 0 to 3) bringing subjectivity to the analysis. Tribun Health has developed AI applications for quantitative histopathological analysis of NASH tissue sections to standardize and improve the drug development journey. These deep learning-based applications can identify and quantify the relevant histopathological features (steatosis, fibrosis, ballooning, and inflammation) with detailed reports.